BNP Paribas Financial Markets’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-8,654
| Closed | -$113K | – | 5834 |
|
|
2025
Q4 | $113K | Sell |
8,654
-125,486
| -94% | -$1.5M | ﹤0.01% | 4323 |
|
|
2025
Q3 | $977K | Buy |
134,140
+30,574
| +30% | +$207K | ﹤0.01% | 3154 |
|
|
2025
Q2 | $555K | Buy |
103,566
+56,006
| +118% | +$271K | ﹤0.01% | 3265 |
|
|
2025
Q1 | $254K | Buy |
47,560
+41,988
| +754% | +$294K | ﹤0.01% | 3579 |
|
|
2024
Q4 | $49.8K | Buy |
+5,572
| New | +$59.2K | ﹤0.01% | 4437 |
|
|
2022
Q4 | – | Sell |
-119
| Closed | -$1.08K | – | 4090 |
|
|
2022
Q3 | $1.08K | Buy |
+119
| New | +$798 | ﹤0.01% | 4419 |
|
|
2021
Q3 | – | Sell |
-145
| Closed | -$1.84K | – | 4011 |
|
|
2021
Q2 | $1.84K | Sell |
145
-301
| -67% | -$3.91K | ﹤0.01% | 3893 |
|
|
2021
Q1 | $7.74K | Sell |
446
-127
| -22% | -$2.29K | ﹤0.01% | 3842 |
|
|
2020
Q4 | $7.36K | Sell |
573
-97
| -14% | -$1.73K | ﹤0.01% | 3944 |
|
|
2020
Q3 | $24.9K | Buy |
670
+557
| +493% | +$22.1K | ﹤0.01% | 3755 |
|
|
2020
Q2 | $4.35K | Buy |
+113
| New | +$4.03K | ﹤0.01% | 4061 |
|
|
2016
Q1 | – | Sell |
-12
| Closed | -$5.79K | – | 2695 |
|
|
2015
Q4 | $5.79K | Sell |
12
-2
| -14% | -$960 | ﹤0.01% | 3448 |
|
|
2015
Q3 | $6.75K | Buy |
+14
| New | +$10K | ﹤0.01% | 3465 |
|
BNP Paribas Financial Markets's ATXS Position: Q1 2026 in Review
BNP Paribas Financial Markets sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 8,654 shares — an estimated $113K sold.
BNP Paribas Financial Markets first reported a position in ATXS in Q3 2015 and held it in 13 quarters. The position peaked at $977K in Q3 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- BNP Paribas Financial Markets reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- BNP Paribas Financial Markets sold 8,654 Astria Therapeutics shares in Q1 2026, an estimated $113K.
- BNP Paribas Financial Markets first reported a position in Astria Therapeutics in Q3 2015 and held it in 13 quarters.
- BNP Paribas Financial Markets's Astria Therapeutics position peaked at $977K in Q3 2025.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.